Organoid teams are entering a phase where reviewers ask what the assay can inform, compared with what, and under which uncertainty. The strategic task is to turn model biology into a claim package that survives diligence, funding review, and regulatory-science discussion.

LLMs can speed up evidence work. But if you can’t reproduce and audit what the model changed, your “AI-enabled” pipeline can become a credibility liability.

**Advanced Therapy (ATMP) projects often fail from poor decision-making, not weak science. FRESCI tackles this bottleneck by structuring uncertainty, aligning evidence with strategic goals, and applying proactive regulatory science. Our focus: smarter decisions and clear thinking to navigate ATMP complexity and translate scientific potential into approved, accessible therapies.